Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that it will invest USD30bn in research, development, and manufacturing infrastructure across the United States over the next five years.

The plan includes significant capital projects and expanded clinical trial activity, with the United States expected to become the company's leading global hub for studies and participants.

As part of the strategy, GSK unveiled a USD1.2bn investment focused on advanced manufacturing facilities, artificial intelligence, and digital technologies. This initiative aims to accelerate biopharma innovation and strengthen US production capabilities for domestic markets.

Key projects include construction of a biologics flex factory in Upper Merion, Pennsylvania, starting in 2026, to develop medicines targeting respiratory diseases such as COPD and asthma, as well as a range of cancers. Additional investments will enhance AI integration, drug substance production, and auto-injector device assembly across existing sites in Pennsylvania, North Carolina, Maryland, and Montana.

The announcement follows GSK's USD800m facility expansion at its Marietta, Pennsylvania site in October 2024. Combined, these projects bring US manufacturing commitments to approximately USD2bn within the past year, adding hundreds of highly skilled roles to GSK's 15,000-employee US workforce.